



J B Chemicals forays into nephrology segment in India

06 May 2021 | News

Company to launch seven products in the division that will focus on the management of hypertension in Chronic Kidney Disease to End-stage renal disease

J.B. Chemicals & Pharmaceuticals, based in Mumbai, has announced its foray into the area of Nephrology with a new dedicated division called “RENOVA” which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.

The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading player in Hypertension with brands like Cilacar® and Nicardia® , JBCPL has now begun to also focus on patients with CKD.

With the introduction of this new division and patient-centric initiatives, JBCPL can help address the medical needs of patients with CKD. The launch of this division will also enable nephrologists and physicians to provide patients with different treatment options and ultimately improve the quality of life in these patients. JBCPL will continue to launch products under this division to achieve its objective of providing holistic support to CKD patients at every stage.

“Being one of leaders in the hypertension segment, we realised that Chronic Kidney Disease is a major issue in the country and the numbers are rising significantly. There are growing cases of hypertension associated with CKD and we believe this initiative will enable us service the growing unmet needs of CKD patients”, said Nikhil Chopra, CEO & Whole Time Director, J.B. Chemicals & Pharmaceuticals Limited.